Zobrazeno 1 - 10
of 1 254
pro vyhledávání: ''
Autor:
Emily Dotson, Narendranath Epperla, Kami J. Maddocks, Megan K Fleming, David A. Bond, Ying Huang, Lapo Alinari, Yazeed Sawalha, John C. Reneau, Beth Christian, Jonathan E. Brammer, Robert A. Baiocchi
Publikováno v:
Blood Advances
Key Points HDMTX administration on day 1 of (R)CHOP is feasible and compares favorably with reports of HDMTX administration midcycle.Delaying prophylactic HDMTX beyond cycle 1 of (R)CHOP might lower the risks of neutropenic fever and acute kidney inj
Autor:
Melhem Solh, Biju George, Mariam H Johnson, Vikas Gupta, Daniel J. Weisdorf, Michael R. Grunwald, Wael Saber, Andrew St. Martin, Minoo Battiwalla, Christopher G. Kanakry, Rohtesh S. Mehta, Mary Eapen, Corey Cutler, Christopher Bredeson, Ryotaro Nakamura, Filippo Milano, Taiga Nishihori, Edward A. Copelan, Asad Bashey, Alberto Mussetti, Hany Elmariah, Mei-Jie Zhang
Publikováno v:
Blood Adv
We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to 2017, using the Center for Internatio
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
Amy E. DeZern, Kenneth R. Cooke, Carol Ann Huff, Nina D. Wagner-Johnston, Richard J. Jones, Marianna Zahurak, Ivan Borrello, Philip H. Imus, Gary L. Rosner, Javier Bolaños-Meade, Leo Luznik, Robert A. Brodsky, Richard F. Ambinder, Lode J. Swinnen, Douglas E. Gladstone, Ephraim J. Fuchs, Heather J. Symons
Publikováno v:
Blood Advances. 4:1770-1779
Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA-haploidentical (haplo) donors after reduced-intensity conditioning with intensive graft-v
Autor:
Cheng Cheng, Raul C. Ribeiro, Francisco Pedrosa, Marcia Pedrosa, Ester Vinhas, Elaine Coustan-Smith, Alessandra Maria de Luna Ramos, Arli Pedrosa, Norma Lucena-Silva, Gaston K. Rivera, Yinmei Zhou, Dario Campana, Mecneide Mendes Lins
Publikováno v:
Blood. 135:1458-1466
Treatment-related mortality is common among children with acute lymphoblastic leukemia (ALL) treated in poor-resource settings. We applied a simplified flow cytometric assay to identify patients with precursor B-cell ALL (B-ALL) at very low risk (VLR
Autor:
Rebeca Bailén, José Luis Díez-Martín, Pascual Balsalobre, David P. Serrano, Ismael Buño, Nieves Dorado, Laura Solán, Maria Jesus Pascual-Cascon, Carolina Martínez-Laperche, Abel García Sola, Ana Isabel Gallardo-Morillo, Mi Kwon, Javier Anguita, Cristina Muñoz
Publikováno v:
Blood Advances. 3:3351-3359
Posttransplant cyclophosphamide (PTCy) effectively prevents graft-versus-host disease (GVHD) after HLA-haploidentical hematopoietic stem cell transplantation (HSCT). The use of PTCy in HLA-identical HSCT is less explored. We conducted a retrospective
Autor:
Hagop M. Kantarjian, Nicholas J. Short, Guillaume Richard-Carpentier, Joseph D. Khoury, Elias Jabbour, Nitin Jain, Siba El Hussein, Farhad Ravandi, Philip A. Thompson, Kiyomi Morita, Bachar Samra
Publikováno v:
Blood Advances.
Burkitt leukemia/lymphoma (BL) and high-grade B-cell lymphoma (HGBL) have a high incidence of central nervous system (CNS) involvement, which is associated with poor prognosis. The hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone pl
Autor:
Li Gao, Jie Li, Yi Wang, Jing Ling, Jianqin Li, Peifang Xiao, Jian Pan, Yixin Hu, Shaoyan Hu, Shuting Jiang, Qianfei Wang, Cheng Cheng, Shengqin Cheng, Fang Fang, Yanhua Yao, Jun Lu, Xinchang Zheng, Raul C. Ribeiro, Hailong He, Liyan Fan, Aili Chen, Junjie Fan
Publikováno v:
Blood Adv
Treatment refusal and death as a result of toxicity account for most treatment failures among children with acute myeloid leukemia (AML) in resource-constrained settings. We recently reported the results of treating children with AML with a combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1da7a7d652976ced512f7c861f415e8
https://europepmc.org/articles/PMC8045515/
https://europepmc.org/articles/PMC8045515/
Autor:
Simona Berardi Vilei, Andreas Lohri, Mario Bargetzi, Ulrich Mey, Micaela Hernberg, Stefan Dirnhofer, Thilo Zander, Ann-Sofie Johansson, Peter de Nully Brown, Walter Mingrone, Eva Kimby, Bjørn Østenstad, Urban Novak, Daniel Rauch, Björn E. Wahlin, Fatime Krasniqi, Felicitas Hitz, Emanuele Zucca, Michele Ghielmini, Stefanie Hayoz, Hans Hagberg, Hanne Skjerven Bersvendsen, Hanne Hawle, Andrés J.M. Ferreri, Anna Vanazzi, Stephanie Rondeau
Publikováno v:
Blood. 134:353-362
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic the
Autor:
Julie M. Gastier-Foster, Eileen Stonerock, Nyla A. Heerema, Lingyun Ji, Naomi J. Winick, Bruce Bostrom, Meenakshi Devidas, Xinxin Xu, Stephen P. Hunger, Linda C. Stork, Karen R. Rabin, Yousif Matloub, Paul S. Gaynon, William L. Carroll, Johann Hitzler
Publikováno v:
Blood Advances. 3:1647-1656
The Children’s Cancer Group 1991 study was a clinical trial for children with National Cancer Institute standard-risk acute lymphoblastic leukemia (ALL). This trial demonstrated that 5 doses of vincristine and escalating IV methotrexate (MTX) witho